Centessa Pharmaceuticals Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Centessa PharmaceuticalsDer Gewinn des Unternehmens wird voraussichtlich um 2.1% pro Jahr sinken, während der Jahresumsatz voraussichtlich um 81.8% pro Jahr wachsen wird. Der Gewinn pro Aktie wird voraussichtlich wachsen um 4.2% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich -64.3% betragen.

Wichtige Informationen

-2.1%

Wachstumsrate der Gewinne

4.2%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	28.4%
Wachstumsrate der Einnahmen	81.8%
Zukünftige Eigenkapitalrendite	-64.3%
Analystenabdeckung	Good
Zuletzt aktualisiert	20 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Is Centessa Pharmaceuticals (NASDAQ:CNTA) Using Debt Sensibly?

Nov 14

Centessa Pharmaceuticals: Progressing SerpinPC Through Registrational Trials In Hemophilia B

Sep 25

Centessa Pharmaceuticals (NASDAQ:CNTA) Has Debt But No Earnings; Should You Worry?

Aug 15

Centessa: Hemophilia B Data Readout In 2024 Is Major Turning Point

Apr 24

Health Check: How Prudently Does Centessa Pharmaceuticals (NASDAQ:CNTA) Use Debt?

Mar 07

Gewinn- und Umsatzwachstumsprognosen

NasdaqGS:CNTA - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	9	-213	-183	-217	5
12/31/2025	N/A	-187	-160	-177	6
12/31/2024	N/A	-173	-160	-159	6
9/30/2024	7	-161	-130	-130	N/A
6/30/2024	7	-157	-146	-146	N/A
3/31/2024	7	-138	-150	-150	N/A
12/31/2023	7	-151	-161	-160	N/A
9/30/2023	N/A	-157	-182	-181	N/A
6/30/2023	N/A	-173	-183	-183	N/A
3/31/2023	N/A	-212	-199	-198	N/A
12/31/2022	N/A	-216	-202	-201	N/A
9/30/2022	N/A	-234	-201	-205	N/A
6/30/2022	N/A	-220	-195	-199	N/A
3/31/2022	N/A	-197	-169	-173	N/A
12/31/2021	N/A	-381	-136	-136	N/A
9/30/2021	N/A	-324	-88	-83	N/A
6/30/2021	N/A	-286	-56	-52	N/A
3/31/2021	N/A	-246	-24	-20	N/A
12/31/2020	N/A	-11	-11	-11	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: CNTA wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: CNTA wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: CNTA wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: CNTA wird im nächsten Jahr voraussichtlich keine Einnahmen haben.

Hohe Wachstumseinnahmen: CNTA wird im nächsten Jahr voraussichtlich keine Einnahmen haben.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: CNTA wird voraussichtlich in 3 Jahren unrentabel sein.

Centessa Pharmaceuticals Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target increased by 8.2% to US$28.29

Price target increased by 10% to US$16.00

Price target increased by 9.2% to US$14.20

Price target increased by 18% to US$7.08

Price target decreased to US$6.00

Recent updates

New major risk - Revenue and earnings growth

Price target increased by 8.2% to US$28.29

Is Centessa Pharmaceuticals (NASDAQ:CNTA) Using Debt Sensibly?

Centessa Pharmaceuticals Initiates Phase 2 Trial with ORX750, a Novel Orexin Receptor 2 (OX2R) Agonist

CEO & Director recently sold US$864k worth of stock

CEO & Director notifies of intention to sell stock

Chief Business Officer recently sold US$261k worth of stock

Centessa Pharmaceuticals: Progressing SerpinPC Through Registrational Trials In Hemophilia B

CEO & Director notifies of intention to sell stock

Centessa Pharmaceuticals plc has filed a Follow-on Equity Offering in the amount of $150 million.

Chief Business Officer notifies of intention to sell stock

Price target increased by 10% to US$16.00

Centessa Pharmaceuticals plc Announces Positive Interim Phase 1 Clinical Data with Its Novel Orexin Receptor 2 (OX2R) Agonist, Orx750, in Acutely Sleep-Deprived Healthy Volunteers

CEO & Director notifies of intention to sell stock

Centessa Pharmaceuticals (NASDAQ:CNTA) Has Debt But No Earnings; Should You Worry?

Price target increased by 9.2% to US$14.20

Centessa Pharmaceuticals plc Announces Chief Financial Officer Changes

Insufficient new directors

Centessa Pharmaceuticals plc has filed a Follow-on Equity Offering in the amount of $100 million.

Centessa Pharmaceuticals plc has filed a Follow-on Equity Offering in the amount of $100 million.

Centessa: Hemophilia B Data Readout In 2024 Is Major Turning Point

Centessa Pharmaceuticals plc has filed a Follow-on Equity Offering in the amount of $100 million.

Centessa Pharmaceuticals plc Announces Open IND for ORX750

Health Check: How Prudently Does Centessa Pharmaceuticals (NASDAQ:CNTA) Use Debt?

New major risk - Revenue and earnings growth

Centessa Pharmaceuticals plc Announces New Data from an Additional 52-Weeks of Continuous Treatment from Third Year (Part 5) of Ongoing Phase 2A Study of Serpinpc for the Treatment of Hemophilia

Centessa Pharmaceuticals plc Announces Dosing of First Subject in Registrational Present-3 Study Evaluating Serpinpc for the Treatment of Hemophilia B with Inhibitors

Centessa Pharmaceuticals plc Announces Preclinical Data Supporting Orx750's Potential as A Best-In-Class Oral Ox2r Agonist for the Treatment of Narcolepsy and Other Sleep-Wake Disorders

Insider notifies of intention to sell stock

World Sleep Congress Releases an Abstract Submit by Centessa Pharmaceuticals plc

New major risk - Revenue and earnings growth

Price target increased by 18% to US$7.08

Centessa Pharmaceuticals Announces Dosing of First Subject in Registrational PRESent-2 Study Evaluating SerpinPC for the Treatment of Hemophilia B Without Inhibitors

New minor risk - Share price stability

Centessa Pharmaceuticals Receives Fast Track Designation from the U.S. FDA for Serpinpc for Hemophilia B

Centessa Pharmaceuticals Announces FDA Clearance of IND Application for Phase 1/2a Clinical Trial of LB101, First LockBody® Candidate, for Solid Tumors

Centessa Pharmaceuticals plc Announces Additional 18-Months of Continued Treatment Data from Open-Label Extension of Phase 2a Study of SerpinPC for Hemophilia

Centessa Pharmaceuticals Announces Karen Anderson as New Chief People Officer

Price target decreased to US$6.00

High number of new and inexperienced directors

The Law Offices of Vincent Wong Announces Class Action Lawsuit Against Centessa Pharmaceuticals plc

Centessa Pharmaceuticals snaps multi-day losing streak; up 10%

Centessa Pharmaceuticals plc Announces Departure of Javad Shahidi as Chief Medical Officer

Centessa Pharmaceuticals plc Announces Class Action Lawsuit Against Centessa Pharmaceuticals plc

Centessa hemophilia B therapy SerpinPC gets FDA orphan drug status

Centessa Pharmaceuticals Announces Non-Human Primate Pharmacokinetic and Safety Data for LB101 (PD-L1xCD47) Demonstrating Potential for Enhanced Therapeutic Index

Centessa Pharmaceuticals GAAP EPS of -$0.69

Centessa Pharmaceuticals Announces Addition of Harris L. Rotman, Phd, as Senior Vice President of Regulatory Affairs

Centessa Pharmaceuticals plc Announces Executive Changes

Centessa Pharmaceuticals plc Announces Board Changes

Centessa Pharmaceuticals plc Announces Poster Presentation of First Preclinical Data for LockBody Program At 2022 ASCO Annual Meeting

Centessa Pharmaceuticals Makes Strategic Decision to Discontinue Clinical Development of Lixivaptan for Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Centessa Pharmaceuticals plc, Annual General Meeting, Jun 30, 2022

High number of new and inexperienced directors

High number of new and inexperienced directors

Centessa Pharmaceuticals Doses First Subject in Global Phase 3 Action Study of Lixivaptan in Autosomal Dominant Polycystic Kidney Disease

Centessa Pharmaceuticals Limited Announces Resignation of Robert M. Califf as Member of the Board of Directors

Checking In On Centessa Pharmaceuticals

Centessa Pharmaceuticals plc Together with Subsidiary Palladio Biosciences, Inc. Initiates Global Phase 3 ACTION Study of Lixivaptan in Autosomal Dominant Polycystic Kidney Disease and Reports Initial Positive Safety Data from ALERT Study

Centessa Pharmaceuticals Announces Positive Topline Data from Proof-of-Concept Study of SerpinPC in Severe Hemophilia A and B Patients Not on Prophylaxis

Centessa Pharmaceuticals stock pops 20%+ intraday to post-IPO high

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken